1. Home
  2. Analysis
  3. Omeprazole
  4. Nuzyra

Omeprazole and Nuzyra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Omeprazole (omeprazole) and Nuzyra (omadacycline tosylate). Common drug interactions include nausea among females and sinusitis among males.

The phase IV clinical study analyzes what interactions people have when they take Omeprazole and Nuzyra. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Omeprazole?

Omeprazole has active ingredients of omeprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 410,631 Omeprazole users. Check the latest studies of Omeprazole.

What is Nuzyra?

Nuzyra has active ingredients of omadacycline tosylate. eHealthMe is studying from 732 Nuzyra users. Check the latest studies of Nuzyra.

On Jul, 17, 2026

20 people who take Omeprazole and Nuzyra together, and have interactions are studied.

Omeprazole and Nuzyra drug interactions.

What are the common drug interactions of Omeprazole and Nuzyra, by gender? *:

female:

  1. Nausea (feeling of having an urge to vomit)
  2. Infective exacerbation of bronchiectasis (severe infective lung disease)
  3. Malaise (a feeling of general discomfort or uneasiness)
  4. Hypoaesthesia oral (reduced sense of touch or sensation in mouth)
  5. Tinnitus (a ringing in the ears)
  6. Acute respiratory failure
  7. Arthralgia (joint pain)
  8. Cough
  9. Drug ineffective
  10. Dyspnoea (difficult or laboured respiration)

male:

  1. Sinusitis (inflammation of sinus)
  2. Infection
  3. Metastases to lymph nodes (cancer spreads to lymph node)
  4. Pneumonia
  5. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  6. Respiratory failure (inadequate gas exchange by the respiratory system)
  7. Sinus tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node)
  8. Weight decreased
  9. Drug hypersensitivity
  10. Hepatic enzyme increased

What are the common drug interactions of Omeprazole and Nuzyra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Cystic fibrosis (disease of the secretary glands)
  2. Hepatic enzyme increased
  3. Liver disorder (liver diseases)

20-29:

n/a

30-39:

  1. Acute lung injury
  2. Arthralgia (joint pain)
  3. Death
  4. Dyspnoea (difficult or laboured respiration)
  5. Dyspnoea exertional (breathlessness or shortness of breath)
  6. Full blood count decreased
  7. Haemoglobin decreased
  8. Implant site extravasation
  9. Pneumonia
  10. Respiratory failure (inadequate gas exchange by the respiratory system)

40-49:

n/a

50-59:

  1. Sinusitis (inflammation of sinus)
  2. Infection
  3. Fall
  4. Intervertebral discitis (infection in the intervertebral disc space)
  5. Nausea (feeling of having an urge to vomit)
  6. Osteomyelitis (infection of bone)
  7. Spinal fracture (fracture in one of vertebrae)
  8. Drug ineffective
  9. Fatigue (feeling of tiredness)
  10. Pneumonia

60+:

  1. Hypoaesthesia oral (reduced sense of touch or sensation in mouth)
  2. Tinnitus (a ringing in the ears)
  3. Constipation
  4. Diarrhoea
  5. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Nausea (feeling of having an urge to vomit)
  8. Vomiting
  9. Acute respiratory failure
  10. Hypoxia (low oxygen in tissues)

What are the existing conditions these people have? *

  1. Mycobacterium Abscessus Infection (rapid growing bacterial infection): 5 people, 25.00%
  2. Mycobacterial Infection: 3 people, 15.00%
  3. Pneumonia: 3 people, 15.00%
  4. Skin Infection: 2 people, 10.00%
  5. Limb Injury: 1 person, 5.00%
  6. Cystic Fibrosis (disease of the secretary glands): 1 person, 5.00%
  7. Granuloma (a small area of inflammation due to tissue injury): 1 person, 5.00%
  8. Heart Rate Increased: 1 person, 5.00%
  9. Hidradenitis (chronic disease of a type of sweat gland): 1 person, 5.00%
  10. Immunodeficiency Common Variable: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Omeprazole and Nuzyra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Omeprazole and Nuzyra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Omeprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nuzyra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omeprazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nuzyra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on omeprazole and omadacycline tosylate (the active ingredients of Omeprazole and Nuzyra, respectively), and Omeprazole and Nuzyra (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.